Mathias Pamminger

Mathias Pamminger

Auto-generated profile, based on publicly available information

Mathias Pamminger

University Clinic of Radiology, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in The Knee
Verified
Journal Article
Closed access
ARArmin Runer
Armin Runer
SBStephan Birkmaier
Stephan Birkmaier
MPMathias Pamminger
Mathias Pamminger
SRSimon Reider
Simon Reider
EHElmar Herbst
Elmar Herbst
CFChristian Fink
Christian Fink

17 October 2023 in Circulation
Verified
Journal Article
Closed access
MRMartin Reindl
Martin Reindl
ILIvan Lechner
Ivan Lechner
MHMagdalena Holzknecht
Magdalena Holzknecht
CTChristina Tiller
Christina Tiller
PFPriscilla Fink
Priscilla Fink
SRSebastian Reinstadler
Sebastian Reinstadler
BACKGROUND: Computed tomography (CT) is recommended for guiding transcatheter aortic valve replacement (TAVR). However, a sizable proportion of TAVR candidates have chronic kidney disease, in whom the use of iodinated contrast media is a limitation. Cardiac magnetic resonance imaging (CMR) is a promising alternative, but randomized data comparing the effectiveness of CMR-guided versus CT-guided TAVR are lacking. METHODS: An investigator-initiated, prospective, randomized, open-label, noninferiority trial was conducted at 2 Austrian heart centers. Patients evaluated for TAVR according to the inclusion criteria (severe symptomatic aortic stenosis) and exclusion criteria (contraindication to CMR, CT, or TAVR, a life expectancy <1 year, or chronic kidney disease level 4 or 5) were randomized (1:1) to undergo CMR or CT guiding. The primary outcome was defined according to the Valve Academic Research Consortium–2 definition of implantation success at discharge, including absence of procedural mortality, correct positioning of a single prosthetic valve, and proper prosthetic valve performance. Noninferiority was assessed using a hybrid modified intention-to-treat/per-protocol approach on the basis of an absolute risk difference margin of 9%. RESULTS: Between September 11, 2017, and December 16, 2022, 380 candidates for TAVR were randomized to CMR-guided (191 patients) or CT-guided (189 patients) TAVR planning. Of these, 138 patients (72.3%) in the CMR-guided group and 129 patients (68.3%) in the CT-guided group eventually underwent TAVR (modified intention-to-treat cohort). Of these 267, 19 patients had protocol deviations, resulting in a per-protocol cohort of 248 patients (121 CMR-guided, 127 CT-guided). In the modified intention-to-treat cohort, implantation success was achieved in 129 patients (93.5%) in the CMR group and in 117 patients (90.7%) in the CT group (between-group difference, 2.8% [90% CI, −2.7% to 8.2%]; P <0.01 for noninferiority). In the per-protocol cohort (n=248), the between-group difference was 2.0% (90% CI, −3.8% to 7.8%; P <0.01 for noninferiority). CONCLUSIONS: CMR-guided TAVR was noninferior to CT-guided TAVR in terms of device implantation success. CMR can therefore be considered as an alternative for TAVR planning. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03831087.

5 January 2017 in European Radiology
Verified
Journal Article
Closed access
PDF file
AKAndrea Sabine Klauser
Andrea Sabine Klauser
MPMathias Pamminger
Mathias Pamminger
EHEthan J. Halpern
Ethan J. Halpern
MEMohamed M. H. Abd Ellah
Mohamed M. H. Abd Ellah
BMBernhard Moriggl
Bernhard Moriggl
WJWerner R. Jaschke
Werner R. Jaschke

1 May 2017 in Radiology
Verified
Journal Article
Closed access
AKAndrea Sabine Klauser
Andrea Sabine Klauser
MPMathias J. Pamminger
Mathias J. Pamminger
EHEthan J. Halpern
Ethan J. Halpern
MEMohamed M. H. Abd Ellah
Mohamed M. H. Abd Ellah
BMBernhard Moriggl
Bernhard Moriggl
WJWerner R. Jaschke
Werner R. Jaschke
The addition of sonoelastography to B-mode US provided a statistically significant improvement in the agreement between imaging and histologic results compared with the use of B-mode US alone (P < .02), although the improvement in sensitivity from 55% to 73% was not statistically significant (P = .15); sonoelastography may be a useful adjunctive tool with B-mode US for evaluation of medial epicondylitis. PurposeTo determine the correlation of the results of conventional B-mode ultrasonography (US) and compression sonoelastography with histologic results in common flexor tendons of the elbow in human cadavers.Materials and MethodsTwenty-five common flexor tendons were evaluated in 16 fresh, unembalmed cadavers of 11 women with a median age of 85 years (range, 71–101 years) and five men with a median age of 78 years (range, 70–88 years). Informed consent was provided according to the last will of the donors. B-mode US results were classified as grade 1, normal tendon with homogeneous fibrillar pattern; grade 2, tendon thickening or hypoechoic areas and/or calcifications in less than 30% of the tendon; or grade 3, hypoechoic areas and/or calcifications greater than 30% of the tendon. Sonoelastographic results were grade 1, blue (hardest) to green (hard); grade 2, yellow (soft); and grade 3, red (softest). The intraclass correlation coefficient was calculated to determine agreement with histologic findings fo...

1 June 2025 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
Felix TrogerFelix Troger
Felix Troger
MPMathias Pamminger
Mathias Pamminger
PPPaulina Poskaite
Paulina Poskaite
MRMartin Reindl
Martin Reindl
MHMagdalena Holzknecht
Magdalena Holzknecht
AMAgnes Mayr
Agnes Mayr
BACKGROUND: Microvascular injury in the course of acute ST-segment–elevation myocardial infarction (STEMI) has been identified as determinant of adverse outcomes and manifests as microvascular obstruction (MVO). MVO has long been regarded as a transient finding, vanishing within a few weeks after infarction. However, recent studies have shown that it may persist beyond the early phase, resulting in adverse remodeling. However, its clinical implications remain unclear. This study aims to evaluate the association of MVO persistence and major adverse cardiac events after STEMI. METHODS: In total, 609 patients with revascularized first-time STEMI underwent cardiac magnetic resonance imaging (CMR) at 4 days, 4 months, and 12 months after STEMI to assess MVO, infarct size, and left ventricular function. Major adverse cardiac events were defined as composite of death, reinfarction, and new congestive heart failure within a median interval of 3.2 years. RESULTS: Baseline MVO was present in 365 (60%) patients and persisted in 35 (10%) patients at 4-month CMR and in 20 (5%) patients at 12-month CMR. Compared with transient MVO not present at follow-up, patients with MVO persistence ≥4 months were more likely to experience major adverse cardiac events during follow-up (29% versus 13%; P =0.016). Within patients with MVO, those with MVO persistence had lower left ventricular ejection fraction ( P =0.002), larger infarcts ( P =0.00001), and more frequent intramyocardial hemorrhage ( P =0.001) at baseline CMR. CONCLUSIONS: Persistent MVO after STEMI occurs in up to 10% of patients with baseline MVO and is linked to major adverse cardiac events. Patients with MVO persistence had larger infarcts, lower left ventricular function, and more frequent intramyocardial hemorrhage at baseline CMR. All patients with MVO persisting ≥12 months initially showed intramyocardial hemorrhage.

20 June 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JHJohannes Holfeld
Johannes Holfeld
FNFelix Nägele
Felix Nägele
LPLeo Pölzl
Leo Pölzl
CEClemens Engler
Clemens Engler
MGMichael Graber
Michael Graber
MGMichael Grimm
Michael Grimm
In chronic ischaemic heart failure, revascularisation strategies control symptoms but are less effective in improving left ventricular ejection fraction (LVEF). The aim of this trial is to investigate the safety of cardiac shockwave therapy (SWT) as a novel treatment option and its efficacy in increasing cardiac function by inducing angiogenesis and regeneration in hibernating myocardium. In this single-blind, parallel-group, sham-controlled trial (cardiac shockwave therapy for ischemic heart failure, CAST-HF; NCT03859466) patients with LVEF ≤40% requiring surgical revascularisation were enrolled. Patients were randomly assigned to undergo direct cardiac SWT or sham treatment in addition to coronary bypass surgery. The primary efficacy endpoint was the improvement in LVEF measured by cardiac magnetic resonance imaging from baseline to 360 days. Overall, 63 patients were randomized, out of which 30 patients of the SWT group and 28 patients of the Sham group attained 1-year follow-up of the primary endpoint. Greater improvement in LVEF was observed in the SWT group (Δ from baseline to 360 days: SWT 11.3%, SD 8.8; Sham 6.3%, SD 7.4, P = .0146). Secondary endpoints included the 6-minute walking test, where patients randomized in the SWT group showed a greater Δ from baseline to 360 days (127.5 m, SD 110.6) than patients in the Sham group (43.6 m, SD 172.1) (P = .028) and Minnesota Living with Heart Failure Questionnaire score on day 360, which was 11.0 points (SD 19.1) for the SWT group and 17.3 points (SD 15.1) for the Sham group (P = .15). Two patients in the treatment group died for non-device-related reasons. In conclusion, the CAST-HF trial indicates that direct cardiac SWT, in addition to coronary bypass surgery improves LVEF and physical capacity in patients with ischaemic heart failure. Direct cardiac shockwave therapy (SWT) in addition to coronary artery bypass graft (CABG) surgery improves left ventricular ejection fraction (LVEF), physical capacity and quality of life in patients with ischaemic heart failure. 6MWT, 6-min walking test; FUP, follow-up; GDMT, guideline-directed medical therapy; NYHA, New York Heart Association; iCMP, ischaemic cardiomyopathy